Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Feb 28, 2024
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -
